![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Robertson J.F.R.
Publisher: Adis International
ISSN: 0312-5963
Source: Clinical Pharmacokinetics, Vol.43, Iss.8, 2004-01, pp. : 529-538
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Fulvestrant as EFECTive as exemestane in advanced breast cancer
Inpharma, Vol. 1, Iss. 1570, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Fulvestrant: benefits at acceptable costs in advanced breast cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 571, 2009-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Fulvestrant looks on track to fulfil expectations in advanced breast cancer
Inpharma, Vol. 1, Iss. 1315, 2001-01 ,pp. :